Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more) Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AnaptysBio Inc ANAB

Healthcare Biotechnology
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032... see more

Recent & Breaking News (NDAQ:ANAB)

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 7 days ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

GlobeNewswire 7 days ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

GlobeNewswire 7 days ago

Actym Therapeutics Appoints Thomas Smart as CEO

PR Newswire April 24, 2024

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 11, 2024

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire February 29, 2024

Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

GlobeNewswire January 31, 2024

Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals

GlobeNewswire November 27, 2023

Anaptys Named a BioSpace 2024 Best Places to Work Winner

GlobeNewswire November 7, 2023

Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 2, 2023

Anaptys Announces Participation in November Investor Conferences

GlobeNewswire November 1, 2023

Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress

GlobeNewswire October 11, 2023

Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25

GlobeNewswire October 9, 2023

Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

GlobeNewswire October 9, 2023

AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

GlobeNewswire September 18, 2023

AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

GlobeNewswire September 12, 2023

AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 7, 2023

AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GlobeNewswire July 31, 2023

AnaptysBio Announces Participation in Upcoming Investor Conferences

GlobeNewswire May 30, 2023

AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

GlobeNewswire May 11, 2023